ATE505489T1 - Tgf-beta-1-spezifische antikörper - Google Patents
Tgf-beta-1-spezifische antikörperInfo
- Publication number
- ATE505489T1 ATE505489T1 AT06750860T AT06750860T ATE505489T1 AT E505489 T1 ATE505489 T1 AT E505489T1 AT 06750860 T AT06750860 T AT 06750860T AT 06750860 T AT06750860 T AT 06750860T AT E505489 T1 ATE505489 T1 AT E505489T1
- Authority
- AT
- Austria
- Prior art keywords
- tgf
- beta
- specific antibodies
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67408205P | 2005-04-22 | 2005-04-22 | |
| PCT/US2006/014943 WO2006116002A2 (en) | 2005-04-22 | 2006-04-20 | Tgf beta 1 specific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505489T1 true ATE505489T1 (de) | 2011-04-15 |
Family
ID=37192643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06750860T ATE505489T1 (de) | 2005-04-22 | 2006-04-20 | Tgf-beta-1-spezifische antikörper |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7619069B2 (de) |
| EP (1) | EP1874818B1 (de) |
| JP (1) | JP5070200B2 (de) |
| KR (1) | KR100978684B1 (de) |
| CN (1) | CN101163719A (de) |
| AT (1) | ATE505489T1 (de) |
| AU (1) | AU2006240056B2 (de) |
| BR (1) | BRPI0608376A8 (de) |
| CA (1) | CA2607448C (de) |
| CY (1) | CY1111518T1 (de) |
| DE (1) | DE602006021292D1 (de) |
| DK (1) | DK1874818T3 (de) |
| EA (1) | EA016038B1 (de) |
| ES (1) | ES2361269T3 (de) |
| HR (1) | HRP20110334T1 (de) |
| IL (1) | IL186775A (de) |
| NO (1) | NO20076003L (de) |
| PL (1) | PL1874818T3 (de) |
| PT (1) | PT1874818E (de) |
| RS (1) | RS51845B (de) |
| SI (1) | SI1874818T1 (de) |
| UA (1) | UA93201C2 (de) |
| WO (1) | WO2006116002A2 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036460A2 (en) * | 2008-09-29 | 2010-04-01 | Centocor Ortho Biotech Inc. | Anti-cd147 antibodies, methods, and uses |
| EP2364370B1 (de) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Verfahren zur prognose von akuter niereninsuffizienz |
| WO2010077831A1 (en) * | 2008-12-16 | 2010-07-08 | Tod Lauerman | Targeted cytokine for treatment of diseases |
| EP2376110B1 (de) | 2009-01-09 | 2019-03-13 | Seattle Genetics, Inc. | Wöchentliche dosierungskonzepte für anti-cd30-vc-pab-mmae-antikörper-wirkstoff-konjugate |
| EP2688908B1 (de) | 2011-03-23 | 2017-06-21 | Option Pharmaceuticals, LLC | Gezieltes cytokin zur behandlung von muskelskeletterkrankungen |
| LT2714735T (lt) * | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| HK1198689A1 (en) | 2011-10-25 | 2015-05-29 | Prothena Biosciences Limited | Antibody formulations and methods |
| EP2822592B1 (de) * | 2012-03-08 | 2018-08-15 | Ludwig Institute for Cancer Research Limited | Spezifische tgf-1-antikörper und verfahren sowie verwendungen davon |
| WO2013134665A1 (en) | 2012-03-08 | 2013-09-12 | Selig Sealing Products, Inc. | Container sealing member with protected security component and removal tab |
| CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| PL2981822T3 (pl) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| JP6416926B2 (ja) * | 2014-02-19 | 2018-10-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ガン標的化ｉｌ−１２免疫療法 |
| HK1245134A1 (zh) | 2015-01-14 | 2018-08-24 | The Brigham And Women's Hospital, Inc. | 用抗lap单克隆抗体治疗癌症 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) * | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| US11180546B2 (en) | 2016-02-17 | 2021-11-23 | Novartis Ag | TGFbeta 2 antibodies |
| WO2017143451A1 (en) * | 2016-02-26 | 2017-08-31 | Western University | Anti-cd11d antibodies and uses thereof |
| BR112018068340A2 (pt) | 2016-03-11 | 2019-01-15 | Scholar Rock Inc | imunoglobulinas de ligação ao tgfss1 e usos destas |
| AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| AU2017268469C1 (en) * | 2016-05-20 | 2025-01-02 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| KR20240113990A (ko) | 2016-06-27 | 2024-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| WO2018043734A1 (en) * | 2016-09-05 | 2018-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-tgf-beta 1 antibodies and methods of use |
| EP3565839A4 (de) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | Checkpoint-regulatorantagonisten |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2019045086A1 (ja) * | 2017-08-29 | 2019-03-07 | 林化成株式会社 | 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途 |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| CA3077664A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11001635B2 (en) | 2018-06-29 | 2021-05-11 | Gensun Biopharma Inc. | Antitumor antagonists |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| TW202043267A (zh) | 2019-01-30 | 2020-12-01 | 美商供石公司 | TGFβ之LTBP複合物專一性抑制劑及其用途 |
| EP3990116A1 (de) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | Antitumor-antagonist bestehend aus einer mutierten tgfss1-rii-extrazellulären domäne und einem immunoglobulin-gerüst |
| WO2021142427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | TGFβ INHIBITORS AND USE THEREOF |
| JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | ＴＧＦ－β阻害剤及びその使用 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| IL309310A (en) * | 2021-06-18 | 2024-02-01 | Genzyme Corp | Antibody formulations against TGF-beta and their use |
| EP4370148A1 (de) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp-komplex-spezifische inhibitoren von tgf-beta1 und verwendungen davon |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| EP4599088A1 (de) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Verfahren und zusammensetzungen zur klassifizierung und behandlung von lungenkrebs |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU771635B2 (en) | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| EP1646655A2 (de) * | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 liganden |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| AR049292A1 (es) | 2004-06-04 | 2006-07-12 | Genentech Inc | Metodo para tratar lupus con un anticuerpo cd20 |
| EP1931709B1 (de) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc-varianten mit optimierten rezeptorbindungseigenschaften |
-
2006
- 2006-04-20 AT AT06750860T patent/ATE505489T1/de active
- 2006-04-20 HR HR20110334T patent/HRP20110334T1/hr unknown
- 2006-04-20 UA UAA200711364A patent/UA93201C2/ru unknown
- 2006-04-20 AU AU2006240056A patent/AU2006240056B2/en not_active Ceased
- 2006-04-20 PT PT06750860T patent/PT1874818E/pt unknown
- 2006-04-20 ES ES06750860T patent/ES2361269T3/es active Active
- 2006-04-20 WO PCT/US2006/014943 patent/WO2006116002A2/en not_active Ceased
- 2006-04-20 SI SI200631049T patent/SI1874818T1/sl unknown
- 2006-04-20 CN CNA2006800135110A patent/CN101163719A/zh active Pending
- 2006-04-20 RS RS20110195A patent/RS51845B/sr unknown
- 2006-04-20 EA EA200702278A patent/EA016038B1/ru not_active IP Right Cessation
- 2006-04-20 JP JP2008507883A patent/JP5070200B2/ja not_active Expired - Fee Related
- 2006-04-20 BR BRPI0608376A patent/BRPI0608376A8/pt not_active IP Right Cessation
- 2006-04-20 DK DK06750860.6T patent/DK1874818T3/da active
- 2006-04-20 EP EP06750860A patent/EP1874818B1/de active Active
- 2006-04-20 PL PL06750860T patent/PL1874818T3/pl unknown
- 2006-04-20 CA CA2607448A patent/CA2607448C/en not_active Expired - Fee Related
- 2006-04-20 KR KR1020077024149A patent/KR100978684B1/ko not_active Expired - Fee Related
- 2006-04-20 DE DE602006021292T patent/DE602006021292D1/de active Active
-
2007
- 2007-10-18 IL IL186775A patent/IL186775A/en not_active IP Right Cessation
- 2007-10-19 US US11/874,952 patent/US7619069B2/en not_active Expired - Fee Related
- 2007-11-21 NO NO20076003A patent/NO20076003L/no not_active Application Discontinuation
-
2009
- 2009-10-15 US US12/579,447 patent/US8128927B2/en not_active Expired - Fee Related
-
2011
- 2011-05-13 CY CY20111100455T patent/CY1111518T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505489T1 (de) | Tgf-beta-1-spezifische antikörper | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| CY2018013I2 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| MY174493A (en) | Binding agents | |
| DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
| DK2135881T3 (da) | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor | |
| CY1113199T1 (el) | Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης | |
| EA201201533A1 (ru) | Prlr-специфическое антитело и его применения | |
| MEP35408A (en) | Tweak binding antibodies | |
| NO20081287A (no) | Brenselsammensetning og fremgangsmåte for å fremstille denne | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| CY1113309T1 (el) | Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα | |
| DK1817055T3 (da) | Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| NO20083609L (no) | Fremgangsmater og sammensetninger for malrettet-RELT | |
| IL185653A0 (en) | Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1 | |
| MX2007013108A (es) | Reactivos que enlazan ccx-ckr2. | |
| WO2006008266A3 (en) | Factor xi-binding proteins | |
| EA202190387A1 (ru) | Антитело к cd38 человека и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1874818 Country of ref document: EP |